학술논문
Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations
Document Type
Article
Author
Salas, María Queralt; Pedraza, Alexandra; Charry, Paola; Suárez-Lledó, María; Rodríguez-Lobato, Luis Gerardo; Brusosa, Marc; Solano, María Teresa; Serrahima, Anna; Nomdedeu, Meritxell; Cid, Joan; Lozano, Miquel; Arcarons, Jordi; de Llobet, Noemi; Rosiñol, Laura; Esteve, Jordi; Urbano-Ispizua, Álvaro; Carreras, Enric; Fernández-Avilés, Francesc; Rovira, Montserrat; Martinez, Carmen
Source
Transplantation and Cellular Therapy; 20230101, Issue: Preprints
Subject
Language
ISSN
26666375; 26666367
Abstract
•Using double-based prophylaxis with PTCY and tacrolimus (PTCY/Tac) in peripheral blood allo-HCT performed from HLA-matched donors reduced the rates of acute and chronic GVHD.•The incidences of grades II-IV and III-IV aGVHD at day +180, and of moderate/severe cGVHD at 2 years in adults receiving PTCY/TAC were of 14.7%, 4.2%, and 2.4%.•The GRFS rates of patients undergoing allo-HCT increased from 16.7% with traditional prophylaxis to 59.1% with the change in regime to PTCY/Tac prophylaxis